Not provided
Not provided
Not provided
Not provided
Not provided
The study was suspended in Taiwan following regulatory authority decision. The overall study under U.S. IND remains active.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The phase I/II, double-blind, randomized study will investigate the efficacy and safety of TACE/TAE treatment with T-ACE Oil in patients with unresectable hepatocellular carcinoma.
Subjects with HCC that meet all eligibility criteria will be admitted to hospital, and TAE or TACE treatment are performed during the hospitalization period; after embolization, subjects are observed in the ward for 1 to 7 days, and evaluated by physician before being discharged. Subjects will be followed up for 7 weeks after treatment for safety and efficacy evaluation.
Phase I part:
12 evaluable subjects will be enrolled sequentially in Phase I part. The first 3 subjects will receive TAE treatment (whether or not they are contraindicated to Doxorubicin) and the following 3 subjects (4th to 6th subjects) will receive TACE treatment. The remaining subjects may receive TAE or TACE treatment. Subjects will be enrolled sequentially in Phase I. For the first six subjects in Phase I, after the subject completes TAE or TACE treatment and is followed for 2 weeks, safety and tolerability data during this period will be reviewed by the safety review committee (SRC); only approved by the SRC, the next subject may start the TAE or TACE treatment. For the 7th to 12th subjects in Phase I, after the subject completes TAE or TACE treatment and is followed until discharge from hospitalization, safety and tolerability data during this period will be reviewed by the safety review committee (SRC); only approved by the SRC, the next subject may start the TAE or TACE treatment. After data for all 12 evaluable subjects are reviewed by SRC and approval is given by the SRC, the study may proceed to Phase II part.
Phase II part:
70 evaluable subjects will be randomized in a 1:1 ratio to receive TAE/TACE treatment by T-ACE Oil or Lipiodol for safety and efficacy evaluation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| T-ACE Oil | Experimental | TAE/TACE treatment was performed with T-ACE Oil. |
|
| Lipiodol | Active Comparator | TAE/TACE treatment was performed with Lipiodol. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| T-ACE Oil | Drug | TAE/TACE treatment was performed with T-ACE Oil. The volume of T-ACE Oil injected will be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor, with room for adjustment per subject's condition or Investigator's judgement. The maximum dose of T-ACE Oil is 0.25 mL/kg/day but not over 15 mL for each treatment. The maximum dose of doxorubicin for a single TACE will be based on standard practice at each site with a maximum of 50 mg. Doxorubicin will be constituted according to labeling and site procedures at a concentration of 10 mg/mL. The emulsion to be injected will have a recommended v/v ratio of 2:1 to 2.5:1 (study product : saline with Doxorubicin dissolved within it). If more than the maximum dose of doxorubicin would be needed to form an emulsion with T-ACE Oil, the remaining volume administered will be study product only. |
| Measure | Description | Time Frame |
|---|---|---|
| Phase I part: Adverse Events as Assessed by CTCAE v5.0 | All Adverse Events (AEs) occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution. Pre-existing conditions will be recorded as baseline on the "Medical History" of CRF. If the pre-existing condition does not change, it does not have to be reported as an AE on subsequent cycles. However, if it deteriorates at any time during the study, it will be recorded as an AE. | Up to 12 weeks |
| Phase I part: Adverse Events of Special Interest (AESIs) | Pulmonary embolism and cerebral embolism will be considered adverse events of special interest (AESIs). AESIs will be analyzed as a safety endpoint. | Up to 12 weeks after treatment |
| Phase I part: Incidence of all serious adverse events (SAEs) after TAE/TACE treatment with T-ACE Oil | 7 weeks after treatment | |
| Phase I part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Measure | Description | Time Frame |
|---|---|---|
| Phase I part: T-ACE Oil deposition type on CT scan after TAE/TACE treatment with T-ACE Oil. | CT or MRI image should be taken at the screening visit, after the TAE or TACE procedure and visit 4 (6 weeks after TAE or TACE procedure). No additional contrast will be administered for the CT after TAE or TACE procedure. V1 and V4 image evaluation will be performed by MRI. V2 image evaluation method will be performed by CT scan. If the subject has had an MRI examination within 28 days before TAE/TACE treatment, the V1 MRI can be skipped. |
Not provided
Inclusion Criteria:
Age of over 18 years (or according to local legal definition of majority).
Patients diagnosed of HCC (Meet at least ONE of the following criteria):
A. Diagnosed via tumor biopsy by pathologists and confirmed by on-service physician. B. High risk patients (viral hepatitis B or C or cirrhotic) with typical liver cancer image appeared on MRI or CT scan.
In very early stage to intermediate stage by BCLC staging (2018 AASLD), HCC tumor numbers ≦ 10, largest HCC tumor size < 7 centimeters (determined by CT, MRI or ultrasound), with liver function at Child-Pugh score[1] ≦ 8.
Disease can be treated by trans-arterial chemoembolization, and can be evaluated by Magnetic resonance imaging (MRI), or computed tomography (CT).
Patients who only require a single TAE/TACE treatment to treat all HCC tumors at once.
Target HCC tumors should have at least 1 tumor that is larger than 1 cm in diameter (determined by CT, MRI or ultrasound). Subjects who have experienced on Lipiodol®-based TAE or TACE treatments are fine to recruit.
May have received local therapy such as TAE, TACE, radiofrequency ablation (RFA) or surgery and remain eligible for study provided the prior therapy was within the following timeframes and the subject has fully recovered from prior therapy: A. TAE/TACE: more than 8 weeks since completion of prior therapy B. RFA: After PI confirm subject is fully recovered from prior therapy based on screening visit physical examination and liver function laboratory tests results. C. Surgery: After PI confirm subject is fully recovered from prior therapy based on screening visit physical examination and liver function laboratory tests results.
Patients able to understand, willing to accept and cooperate with all clinical trial practices.
Willing to sign a written informed consent form.
Exclusion Criteria:
Major branch of portal vein has been invaded by HCC, or the patient has extrahepatic metastasis or other current malignant tumors.
Eligible for curative surgery or transplant as judged by PI.
Evidences of decompensation (Meet at least ONE of the following criteria):
Any of the following findings (but not limit to):
Any of the following laboratory findings:
Performance status Eastern Cooperative Oncology Group (ECOG) of 2 or more.
Patients whose blood vessel are too difficult to perform TACE procedure as judged by PI.
TACE procedure would be performed in areas of the liver where bile ducts are dilated as judged by PI.
Prominent Hepatic arteriovenous (AV) shunt, as judged by PI.
Non-targeted area may be endangered during TACE procedure, as judged by PI.
Patients, who have ever accepted TACE therapy, and cannot gain extra benefits from further embolization treatment.
Allergy or contraindication to iodine, Lipiodol®, allowed contrast agents, allowed Gelfoam suppositories or allowed artery hemostats.
Pregnant females or lactating females.
Male or female subjects with fertility who are unwilling to perform highly effective contraception method.
Subjects who, in the opinion of the investigator, are not suitable to participate in the trial for whatever reason.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Po-Chin Liang, PhD, MD | National Taiwan University Hospital | Principal Investigator |
| Xi-Zhang Lin, MD | T-ACE Medical Co., Ltd | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kaohsiung Veterans General Hospital | Kaohsiung City | 813 | Taiwan | |||
| Tungs' Taichung Metroharbor Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20598571 | Background | Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, Notsumata K, Toya D, Tanaka N, Mitsui T, Matsui O. Chemoembolization for the treatment of large hepatocellular carcinoma. J Vasc Interv Radiol. 2010 Aug;21(8):1226-34. doi: 10.1016/j.jvir.2010.04.015. Epub 2010 Jul 3. | |
| 20175033 | Background |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D004998 | Ethiodized Oil |
| ID | Term |
|---|---|
| D007459 | Iodized Oil |
| D010938 | Plant Oils |
| D009821 | Oils |
| D008055 | Lipids |
| D028321 |
Not provided
Not provided
Phase I/II, interventional study; competitive enrollment, multi study center
Not provided
Not provided
Not provided
|
| Lipiodol | Drug | TAE/TACE treatment was performed with Lipiodol®. The volume of Lipiodol® injected will be 1-1.5 mL/cm based on the diameter (cm) of the treated tumor, with room for adjustment per subject's condition or Investigator's judgement. The maximum dose of T-ACE Oil is 0.25 mL/kg/day but not over 15 mL for each treatment. The maximum dose of doxorubicin for a single TACE will be based on standard practice at each site with a maximum of 50 mg. Doxorubicin will be constituted according to labeling and site procedures at a concentration of 10 mg/mL. The emulsion to be injected will have a recommended v/v ratio of 2:1 to 2.5:1 (study product : saline with Doxorubicin dissolved within it). If more than the maximum dose of doxorubicin would be needed to form an emulsion with Lipiodol®, the remaining volume administered will be study product only. |
|
|
| Phase I part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg)of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase I part: Safety variables evaluation - pulse rate | Pulse rate (beats/min) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - pulse rate | Pulse rate (beats/min) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - pulse rate | Pulse rate (beats/min) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - pulse rate | Pulse rate (beats/min) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - pulse rate | Pulse rate (beats/min) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - pulse rate | Pulse rate (beats/min) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase I part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase I part: Safety variables evaluation - Respiratory rate | Respiratory rate (times/min) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Respiratory rate | Respiratory rate (times/min) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Respiratory rate | Respiratory rate (times/min) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Respiratory rate | Respiratory rate (times/min) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Respiratory rate | Respiratory rate (times/min) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Respiratory rate | Respiratory rate (times/min) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase I part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase I part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase I part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase I part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase I part: Safety variables evaluation - Thyroid function (T3) | T3 (ng/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Thyroid function (T3) | T3 (ng/dL) of subjects will be measured. | 6 weeks after treatment (V4). |
| Phase I part: Safety variables evaluation - Thyroid function (Free T4) | T4 (ng/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Thyroid function (Free T4) | T4 (ng/dL) of subjects will be measured. | 6 weeks after treatment (V4). |
| Phase I part: Safety variables evaluation - Thyroid function (TSH) | TSH (uIU/ml) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - Thyroid function (TSH) | TSH (uIU/ml) of subjects will be measured. | 6 weeks after treatment (V4). |
| Phase I part: Safety variables evaluation - ECG test | Electrocardiogram (ECG) of subjects will be measured. The participants with treatment-related adverse events will be assessed by CTCAE v5.0 | Pre-intervention (V1)(-28 to -1 days) |
| Phase I part: Safety variables evaluation - ECG test | Electrocardiogram (ECG) of subjects will be measured. The participants with treatment-related adverse events will be assessed by CTCAE v5.0 | immediately after the intervention (V2) |
| Phase I part: Safety variables evaluation - ECG test | Electrocardiogram (ECG) of subjects will be measured. The participants with treatment-related adverse events will be assessed by CTCAE v5.0 | 6 weeks after treatment (V4) |
| Phase II part: T-ACE Oil or Lipiodol deposition type on CT scan after TAE/TACE treatment. | CT or MRI image should be taken at the screening visit, after the TAE or TACE procedure and visit 4 (6 weeks after TAE or TACE procedure). No additional contrast will be administered for the CT after TAE or TACE procedure. V1 and V4 image evaluation will be performed by MRI. V2 image evaluation method will be performed by CT scan. If the subject has had an MRI examination within 28 days before TAE/TACE treatment, the V1 MRI can be skipped. | 72 hours after treatment |
| Phase II part: mRECIST overall response at 6 weeks after TAE/TACE treatment. | mRECIST (modified Response Evaluation Criteria in Solid Tumors) overall response and mRECIST target lesion response will be evaluated based on the image taken at the screening visit and at visit 4 (6 weeks after TAE or TACE procedure). mRECIST overall response for each patient will be categorized: Complete response (CR), Partial response (PR), Stable disease (SD), and Progressive disease (PD). mRECIST overall response is based on target lesions and non-target lesions responses and appearance of new lesions and/or extra-hepatic disease. | 6 weeks after treatment. |
| Phase II part: target lesion response at 6 weeks after TAE/TACE treatment. | target lesion response will be evaluated based on the image | 6 weeks after treatment. |
| 72 hours after treatment |
| Phase I part: mRECIST overall response at 6 weeks after TAE/TACE treatment with T-ACE Oil. | mRECIST (modified Response Evaluation Criteria in Solid Tumors) overall response and mRECIST target lesion response will be evaluated based on the image taken at the screening visit and at visit 4 (6 weeks after TAE or TACE procedure). mRECIST overall response for each patient will be categorized: Complete response (CR), Partial response (PR), Stable disease (SD), and Progressive disease (PD). mRECIST overall response is based on target lesions and non-target lesions responses and appearance of new lesions and/or extra-hepatic disease. | 6 weeks after treatment. |
| Phase I part: target lesion response at 6 weeks after TAE/TACE treatment with T-ACE Oil. | target lesion response will be evaluated based on the image | 6 weeks after treatment. |
| Phase II part: Incidence of all adverse events (AEs) after TAE/TACE treatment with T-ACE Oil or Lipiodol. | 7 weeks after treatment |
| Phase II part: Incidence of adverse events of special interest (AESIs) after TAE/TACE treatment with T-ACE Oil or Lipiodol. | 7 weeks after treatment |
| Phase II part: Incidence of all serious adverse events (SAEs) after TAE/TACE treatment with T-ACE Oil or Lipiodol. | 7 weeks after treatment |
| Phase II part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Blood pressures | Blood pressures (including SBP and DBP, unit: mmHg) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase II part: Safety variables evaluation - Pulse rate | Pulse rate (beats/min) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Pulse rate | Pulse rate (beats/min) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Pulse rate | Pulse rate (beats/min) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Pulse rate | Pulse rate (beats/min) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Pulse rate | Pulse rate (beats/min) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Pulse rate | Pulse rate (beats/min) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase II part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Body weight. | Body weight (kilograms) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase II part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Body temperature. | Body temperature (oC) of subjects will be measured. | 7 weeks after treatment (V5) |
| Phase II part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - WBC | WBC (1000/uL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Platelet count | Platelet count (1000/uL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Hb | Hb (g/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - blood urea nitrogen test | BUN (mg/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Bilirubin | Bilirubin-T and Bilirubin-D (mg/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Renal function | Creatinine (mg/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Liver function | AST and ALT (U/L) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | discharge of hospitalization (V2A)(1 to 7 days of discharge of hospitalization) |
| Phase II part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | 2 weeks after treatment (V3) |
| Phase II part: Safety variables evaluation - Coagulation function | Prothrombin time and APTT (seconds) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Thyroid function (T3) | T3 (ng/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Thyroid function (T3) | T3 (ng/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Thyroid function (Free T4) | T4 (ng/dL) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Thyroid function (Free T4) | T4 (ng/dL) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - Thyroid function (TSH) | TSH (uIU/ml) of subjects will be measured. | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - Thyroid function (TSH) | TSH (uIU/ml) of subjects will be measured. | 6 weeks after treatment (V4) |
| Phase II part: Safety variables evaluation - ECG test | each component of Electrocardiogram (ECG) of subjects will be measured. The participants with treatment-related adverse events will be assessed by CTCAE v5.0 | Pre-intervention (V1)(-28 to -1 days) |
| Phase II part: Safety variables evaluation - ECG test | each component of Electrocardiogram (ECG) of subjects will be measured. The participants with treatment-related adverse events will be assessed by CTCAE v5.0 | immediately after the intervention (V2) |
| Phase II part: Safety variables evaluation - ECG test | each component of Electrocardiogram (ECG) of subjects will be measured. The participants with treatment-related adverse events will be assessed by CTCAE v5.0 | 6 weeks after treatment (V4) |
| Taichung |
| 435 |
| Taiwan |
| National Cheng Kung University Hospital | Tainan | 701 | Taiwan |
| National Taiwan University Hospital | Taipei | 100 | Taiwan |
| Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. |
| 26765068 | Background | Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7. |
| 24507426 | Background | Wang Z, Lin M, Lesage D, Chen R, Chapiro J, Gu T, Tacher V, Duran R, Geschwind JF. Three-dimensional evaluation of lipiodol retention in HCC after chemoembolization: a quantitative comparison between CBCT and MDCT. Acad Radiol. 2014 Mar;21(3):393-9. doi: 10.1016/j.acra.2013.11.006. |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |
| Plant Preparations |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |